Mr. Mahatme brings decades of experience in strategic finance, capital formation, and operational leadership to support company’s transformation and growth in autoimmune disease CAMBRIDGE, Mass., July ...
WELLESLEY HILLS, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback